...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

If this works as expected, it would be great to see an Emergency Use Authorization being issued by the FDA.  That would certainly put it on people's radar.

Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when there are no adequate, approved, and available alternatives.

Seems to me we have reasonable shot at this.

masila

Share
New Message
Please login to post a reply